BML 5.07 Increased By ▲ 0.06 (1.2%)
BOP 11.82 Decreased By ▼ -0.05 (-0.42%)
CNERGY 7.15 Decreased By ▼ -0.01 (-0.14%)
CPHL 88.99 Decreased By ▼ -0.30 (-0.34%)
DCL 14.13 Increased By ▲ 0.32 (2.32%)
DGKC 165.80 Decreased By ▼ -0.20 (-0.12%)
FCCL 45.95 Decreased By ▼ -0.40 (-0.86%)
FFL 15.85 Decreased By ▼ -0.13 (-0.81%)
GCIL 28.30 Decreased By ▼ -0.15 (-0.53%)
HUBC 142.10 Decreased By ▼ -0.88 (-0.62%)
KEL 5.13 Decreased By ▼ -0.01 (-0.19%)
KOSM 6.32 Increased By ▲ 0.03 (0.48%)
LOTCHEM 21.79 Increased By ▲ 0.86 (4.11%)
MLCF 83.71 Decreased By ▼ -0.92 (-1.09%)
NBP 120.00 Decreased By ▼ -0.27 (-0.22%)
PAEL 42.90 Decreased By ▼ -0.40 (-0.92%)
PIAHCLA 20.80 Decreased By ▼ -0.35 (-1.65%)
PIBTL 8.69 Increased By ▲ 0.06 (0.7%)
POWER 13.85 Decreased By ▼ -0.16 (-1.14%)
PPL 171.90 Decreased By ▼ -1.60 (-0.92%)
PREMA 44.21 Decreased By ▼ -0.70 (-1.56%)
PRL 33.53 Increased By ▲ 0.36 (1.09%)
PTC 25.32 Increased By ▲ 1.31 (5.46%)
SNGP 121.60 Increased By ▲ 0.51 (0.42%)
SSGC 46.70 Increased By ▲ 0.75 (1.63%)
TELE 8.12 Increased By ▲ 0.07 (0.87%)
TPLP 9.59 Decreased By ▼ -0.13 (-1.34%)
TREET 23.81 Decreased By ▼ -0.48 (-1.98%)
TRG 58.09 Decreased By ▼ -0.34 (-0.58%)
WTL 1.61 Increased By ▲ 0.06 (3.87%)
BR100 13,510 Decreased By -36.8 (-0.27%)
BR30 39,616 Decreased By -125.9 (-0.32%)
KSE100 133,061 Decreased By -309.5 (-0.23%)
KSE30 40,570 Decreased By -135.6 (-0.33%)

Novartis

Novartis pushes back UK cholesterol study's end to 2026 on COVID disruption
Business & Finance

Novartis pushes back UK cholesterol study's end to 2026 on COVID disruption

  • In January 2020, Novartis struck a deal with the National Health Service to use its data to find patients at risk of heart disease for whom conventional treatment had failed. They are due to get Leqvio, which targets "bad cholesterol" that can cause heart attacks and strokes.
  • "With the impact of COVID in the UK, recruitment has been challenging," said John Tsai, Novartis's head of drug development, adding that recruitment is now "starting to get back on track".
Published 27 Apr, 2021 08:45pm
Novartis in talks on helping make COVID-19 vaccines, tests
Business & Finance

Novartis in talks on helping make COVID-19 vaccines, tests

  • Novartis Technical Operations is currently exploring ways in which we can collaborate with our partners in the industry.
  • We are currently in discussions with several companies with a view to supporting the manufacturing of vaccines and components for tests for COVID-19, and we will share details as soon as possible.
Published 28 Jan, 2021 07:07pm